1 of 11

PARTNERSHIPS FOR GLOBAL SURGERY · RESEARCH PROPOSAL

[ Descriptive Project Title]

ONE-SENTENCE PITCH I want to [do what] using [what data, setting or literature] to answer [question], over [X] months.

PRESENTED BY

[Name]

HOME INSTITUTION

[School or program]

COLLABORATORS & SITE

[Name, role, institution, country]

DATE

[DD Month YYYY]

2 of 11

How to use this template

Read this once, fill in every bracket, then delete this slide. Speaker notes have helpful info

DELETE ME

BEFORE YOU BUILD

  • Replace every [bracket]. An unfilled bracket is a visible unanswered question.
  • Slashes mean pick one and delete the rest.
  • Every number gets a source, or the tag (estimate).

TIMING

  • Seven slides, about seven minutes.
  • Detail goes in the speaker notes or the appendix, not on the slide.

HOW TO SPEAK TO IT

  • Say what you do not know
  • End the presentation on your ask

THE ONE THING THIS PRESENTATION IS FOR

Can this be done, by you (with help), with that data, in that time, for that money?

IT WORKS FOR ANY STUDY TYPE

Chart review or cohort · secondary analysis of existing data · systematic or scoping review · survey · qualitative · before-after or randomised comparison · quality improvement. Where a box genuinely does not apply, write "n/a" and say why.

3 of 11

The PICOTT question

Population · Intervention · Comparator · Outcome · Time · Type of study.

P: POPULATION

[Who, where, what age, what condition, what setting or dataset.]

I: INTERVENTION OR EXPOSURE

[What is done, given, or experienced. For observational work, this is the exposure.]

C: COMPARATOR

[Another group, another period, before vs after, or "none, descriptive".]

O: OUTCOME

[The one thing you will measure, defined so a stranger could collect it.]

T: TIME

[Follow-up duration, or the period the data covers.]

T: TYPE OF STUDY

[The design in a few words: chart review, cohort, survey, scoping review, before-after, randomised. Detail on the Study design slide.]

PRIMARY OBJECTIVE

To [verb] the [outcome] among [population] using [data or setting], over [period].

SECONDARY AIM (ONE AT MOST)

[ ] or "none"

4 of 11

Background and the gap

WHY THIS PROBLEM MATTERS

  • [Condition or problem] affects [n / rate] in [population or region]. (Source: [citation, year])
  • [Why now: a new service, a training programme, a policy change, a dataset that just became available.]

WHAT IS ALREADY KNOWN

  • [Finding 1 (author, year)]
  • [Finding 2 (author, year)]
  • [Where existing work falls short, e.g. nothing from this region.]

THE GAP, IN ONE SENTENCE

"No study has [done what] for [which population or setting]."

[Why that gap matters]

WHOSE PRIORITY THIS IS

[Who called this a priority: a clinician at the site, a ministry, a national plan.]

[If the idea is yours, say so, and how you will check it matters locally.]

Appendix B holds your feasibility self-check and a table of what the prior studies found.

5 of 11

Study design

Name the design, say why it fits, and pick its reporting checklist now.

STUDY TYPE, AND WHY IT FITS

Type: [name it plainly: retrospective chart review, cross-sectional survey, before-after study, randomised comparison (non-clinical), scoping review, burden-of-disease analysis…]

[It can show [what]]

[Why this design]

CHECKLIST, ETHICS AND REGISTRATION

Report to: [STROBE / CONSORT 2025 / PRISMA 2020 / GATHER / COREQ / other. See Appendix A]

Ethics: [IRB or local ethics committee approval, or documented waiver] · Consent: [written / verbal / waiver, in what language]

Register only if applicable: [review → PROSPERO, OSF or JBI · prospective study → ClinicalTrials.gov · otherwise not customary]

If randomising: [what is randomised, how, and who measures the outcome]

6 of 11

Data and analysis

WHERE THE DATA COMES FROM, AND WHO IS INCLUDED

  • [Charts, register, public dataset, published studies, questionnaires, tests or assessments.]
  • [Inclusion and exclusion, in one line.]

HOW MUCH DATA I EXPECT, AND HOW I KNOW

  • Expect about [n], based on [a count I did / rows in the dataset / search results] on [date].
  • [Roughly [n] left after exclusions and missing data. (estimate)]

HOW IT GETS COLLECTED

  • [Form or instrument. Validated? Piloted?]
  • [Who collects it, and where it is stored: REDCap / encrypted file.]

HOW IT GETS ANALYSED

  • [Main summary or comparison, and the test or model.]
  • [Sample size or precision, or "need statistics help" (last slide).]

Write the data dictionary and pick the analysis before collecting anything.

7 of 11

Timeline

Shade the months each phase is active. Phases can overlap.

Month 1 = [Month YYYY] Total length: [n] months

Phase

Done when…

Owner

M1

M2

M3

M4

M5

M6

M7

M8

M9

M10

M11

M12

Protocol & data dictionary

Protocol final; every variable defined; registered if applicable

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Ethics & approvals

Approval letter or exempt determination in hand

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Set-up & training

Form built and piloted on [n] records; collectors trained

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Data collection

[n] records reached; completeness checked [how often]

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Analysis

Dataset locked; pre-specified analysis run

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Write-up & sharing back

Draft done; results shared with [whom]

[ ]

​

​

​

​

​

​

​

​

​

​

​

​

Find the ethics committee’s real meeting dates before shading that row.

8 of 11

Team

Who does what, and how much of it. Tasks follow the ICMJE criteria, so authorship is clear later.

TEAM SIZE

[n] people · about [n] hours of other people’s time

[How I estimated it, e.g. 300 records ÷ 10 per hour = 30 hours.]

ROLES I STILL NEED FILLED

[Which role, and what I need to fill it.]

Task / role (ICMJE criterion)

How many needed

Name(s)

Est. hours

Conception & design (1)

[n]

[Your name]

[ ]

Ethics submission & approvals (1)

[n]

[ ]

[ ]

Data acquisition / collection (1)

[n]

[ ]

[ ]

Analysis & interpretation (1)

[n]

[ ]

[ ]

Drafting the manuscript (2)

[n]

[ ]

[ ]

Critical revision & final approval (2, 3)

[n]

[ ]

[ ]

Support roles, not authorship (translation, coordination, data entry)

[n]

[ ]

[ ]

ICMJE authorship needs all four: (1) substantial contribution to conception, design, acquisition, analysis or interpretation; (2) drafting or critically revising it; (3) approving the final version; (4) accountability for the work. A blank name is a gap — say so on the next slide.

9 of 11

What help I need

Tick the two or three you actually need, and write what exactly. Blanks say the rest is covered.

WHAT I NEED HELP WITH

Ethics & approvals

[what exactly, from whom, and by when]

Data access

[what exactly, from whom, and by when]

Statistics

[what exactly, from whom, and by when]

People for the work

[what exactly, from whom, and by when]

In-country & logistics

[what exactly, from whom, and by when]

Funding

[what exactly, from whom, and by when]

Mentorship & oversight

[what exactly, from whom, and by when]

Writing & publication

[what exactly, from whom, and by when]

10 of 11

Appendix A: design families and checklists

Not presented. Find your design here if you are unsure what it is called.

DELETE ME AFTER DECIDING

Design

Report to

Register?

Cohort, case-control, cross-sectional

STROBE

Encouraged if prospective, not required

Chart review, registry or routine data

RECORD

Not customary — IRB or waiver instead

Before-after or non-randomised comparison

TREND

Required if you assign the intervention

Randomised comparison

CONSORT 2025

Required, before the first consent

Burden of disease estimates

GATHER

Not customary

Diagnostic or screening accuracy

STARD 2015

Encouraged if prospective

Prediction model

TRIPOD+AI

Encouraged; OSF is the usual place

Instrument validation or translation

COSMIN

Not customary

Systematic review, meta-analysis

PRISMA 2020

PROSPERO, before screening starts

Scoping review

PRISMA-ScR

OSF — PROSPERO does not take these

Qualitative

COREQ or SRQR

Not customary

Consensus or Delphi

ACCORD

Not customary

Survey

CROSS · CHERRIES for web

Not customary

Quality improvement

SQUIRE 2.0

Not customary

Implementation study

StaRI

Required if an intervention is assigned

Economic evaluation

CHEERS 2022

Follows the study it sits on

Case report or series

CARE

No registry — consent; IRB if >3 cases

THREE THINGS PEOPLE ASK

Report to = the checklist your finished paper must satisfy. EQUATOR keeps them all.

Ethics comes first, and is separate. Almost every study needs IRB or local ethics committee approval, or a documented waiver; primary data collection normally needs participant consent.

Register = required only when you prospectively assign people to an intervention (ICMJE), in ClinicalTrials.gov or a WHO primary registry such as PACTR or CTRI, before the first consent. Reviews register in PROSPERO. Observational work is encouraged, not required.

WHERE TO FIND THEM

equator-network.org

prisma-statement.org

gather-statement.org

crd.york.ac.uk/prospero

osf.io

clinicaltrials.gov

who.int/clinical-trials-registry-platform

11 of 11

Appendix B: before the meeting, and later

Not presented. Prep work: the feasibility self-check, and what the prior studies already show.

DELETE ME AFTER DECIDING

FEASIBILITY SELF-CHECK

The data exists and I can reach it

CONFIRMED · PARTLY · UNKNOWN

The people I need have said yes

CONFIRMED · PARTLY · UNKNOWN

I have the time

CONFIRMED · PARTLY · UNKNOWN

Skills covered, incl. statistics

CONFIRMED · PARTLY · UNKNOWN

Approvals are achievable

CONFIRMED · PARTLY · UNKNOWN

The cost is within reach

CONFIRMED · PARTLY · UNKNOWN

WHAT THE PRIOR STUDIES FOUND (FROM YOUR SCOPING SEARCH)

Study (author, year)

Design, setting, n

Key finding

Gap it leaves

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

[ ]

THE GAP THIS PROJECT FILLS

[One sentence: what none of the studies above did. It should match the gap sentence on the Background slide.]